ARTICLE | Clinical News
Humira adalimumab regulatory update
October 29, 2012 7:00 AM UTC
EMA's CHMP issued a positive opinion to expand the label of Abbott's Humira adalimumab to include treatment of patients aged 6-17 years with severely active Crohn's disease who failed, are intolerant ...